Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDX 301

Drug Profile

CDX 301

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics; Mobista; rhuFlt3L

Latest Information Update: 14 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Merck Sharp & Dohme
  • Class Adjuvants; Antineoplastics; Cytokines; Recombinant proteins
  • Mechanism of Action Fms-like tyrosine kinase 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II B-cell lymphoma; Breast cancer; Head and neck cancer; Non-Hodgkin's lymphoma
  • Phase I Prostate cancer; Solid tumours
  • Discontinued Autoimmune disorders; Infections; Malignant melanoma; Stem cell mobilisation

Most Recent Events

  • 21 Jun 2019 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (SC) (NCT03835533)
  • 01 Apr 2019 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease) in USA (Parenteral) (NCT03789097)
  • 01 Apr 2019 Phase-I/II clinical trials in Head and neck cancer (Combination therapy) in USA (Parenteral) (NCT03789097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top